WELCOME TO The PHARMACEUTICAL REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Boehringer Ingelheim | May 16, 2017
Today, Boehringer Ingelheim inaugurated its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park of Shanghai (China). The site, with the first-phase investment of more than €70 million, is the first and only biopharmaceutical facility established by a leading multinational active biopharmaceutical manufacturer in China utilizing mammalian cell culture technology....
Boehringer Ingelheim | August 25, 2017
Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015. The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3) (1), and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH....
Boehringer Ingelheim | November 03, 2017
Boehringer Ingelheim has linked with US group Dicerna Pharmaceuticals to develop new RNAi therapeutics for liver diseases....
Boehringer Ingelheim | November 09, 2017
The German drugmaker is linking with UK-based MiNA Therapeutics to develop novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA’s small activating RNA (siRNA) therapeutics platform....
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE